TY - JOUR
T1 - Lithium effects on renal functioning
T2 - an expert opinion and management algorithm
AU - Strandhave, Charlotte
AU - Hansen, Hans August Stengaard
AU - Alda, Martin
AU - Bauer, Michael
AU - Berk, Michael
AU - Buspavanich, Pichit
AU - Brandt, Lasse
AU - Carvalho, Andre F.
AU - Duffy, Anne
AU - Forlenza, Orestes
AU - Laursen, Mathilde Frahm
AU - Frye, Mark
AU - Gitlin, Michael
AU - Gomes, Fabiano Alves
AU - Gonzalez-Pinto, Ana
AU - Grof, Paul
AU - Hajek, Tomas
AU - Hovgesen, Sanne V.
AU - Kessing, Lars Vedel
AU - Kupka, Ralph
AU - Lewitzka, Ute
AU - Licht, Rasmus W.
AU - Machado-Vieira, Rodrigo
AU - Malhi, Gin S.
AU - Manchia, Mirko
AU - Post, Robert M.
AU - Murru, Andrea
AU - Nierenberg, Andrew A.
AU - Regeer, Eline
AU - Reininghaus, Eva
AU - Ritter, Phillip
AU - Rybakowski, Janusz
AU - Singh, Balwinder
AU - Sani, Gabriele
AU - Simhandl, Christian
AU - Strawbridge, Rebecca
AU - Suppes, Trisha
AU - Tohen, Mauricio
AU - Tondo, Leonardo
AU - Vieta, Eduard
AU - Young, Allan H.
AU - Nielsen, René Ernst
N1 - Publisher Copyright:
© The Author(s) 2026.
PY - 2026/12
Y1 - 2026/12
N2 - Objective: This expert opinion paper addresses the critical balance between lithium’s therapeutic efficacy in recurrent mood disorders and its potential renal side effects. The objective is to provide evidence-based guidelines to enhance clinical decision-making, prevent emergence of, and mitigate risks associated with lithium-induced renal impairment. Methods: An extensive review of epidemiological, observational, and experimental studies on lithium-induced renal impairment, focusing on its pathophysiology, clinical manifestations, and risk factors was conducted. Expert consensus and recent data were integrated to develop a management algorithm for renal monitoring and intervention. Results: Lithium remains the gold standard for mood stabilization in bipolar disorders, with robust evidence supporting its role in recurrence prevention and suicide risk reduction. While mild to moderate renal impairment is recognized as a risk factor, newer studies show a lower incidence of severe outcomes, such as end-stage kidney disease, necessitating dialysis treatment and renal transplantation, especially with appropriate monitoring, as compared to older studies. This paper addresses pathophysiological mechanisms, including arginine vasopressin resistance and chronic interstitial nephritis, alongside risk factors like rapid initial decline in glomerular filtration rate, early age at treatment initiation, cumulative dosage, mean serum levels of lithium and episodes of lithium intoxication. Effective management strategies, including judicious dosing, routine monitoring, and early nephrology referral, can significantly improve outcomes. Conclusions: Lithium remains an invaluable treatment for recurrent mood disorders, and its benefits often outweigh the risks when managed appropriately. This paper provides a practical framework for clinicians to address renal concerns, emphasizing the importance of systematic monitoring and individualized care. The paper underscores the need for continued research and education of clinicians and patients to optimize lithium use while safeguarding patient health.
AB - Objective: This expert opinion paper addresses the critical balance between lithium’s therapeutic efficacy in recurrent mood disorders and its potential renal side effects. The objective is to provide evidence-based guidelines to enhance clinical decision-making, prevent emergence of, and mitigate risks associated with lithium-induced renal impairment. Methods: An extensive review of epidemiological, observational, and experimental studies on lithium-induced renal impairment, focusing on its pathophysiology, clinical manifestations, and risk factors was conducted. Expert consensus and recent data were integrated to develop a management algorithm for renal monitoring and intervention. Results: Lithium remains the gold standard for mood stabilization in bipolar disorders, with robust evidence supporting its role in recurrence prevention and suicide risk reduction. While mild to moderate renal impairment is recognized as a risk factor, newer studies show a lower incidence of severe outcomes, such as end-stage kidney disease, necessitating dialysis treatment and renal transplantation, especially with appropriate monitoring, as compared to older studies. This paper addresses pathophysiological mechanisms, including arginine vasopressin resistance and chronic interstitial nephritis, alongside risk factors like rapid initial decline in glomerular filtration rate, early age at treatment initiation, cumulative dosage, mean serum levels of lithium and episodes of lithium intoxication. Effective management strategies, including judicious dosing, routine monitoring, and early nephrology referral, can significantly improve outcomes. Conclusions: Lithium remains an invaluable treatment for recurrent mood disorders, and its benefits often outweigh the risks when managed appropriately. This paper provides a practical framework for clinicians to address renal concerns, emphasizing the importance of systematic monitoring and individualized care. The paper underscores the need for continued research and education of clinicians and patients to optimize lithium use while safeguarding patient health.
KW - Arginine vasopressin resistance
KW - Bipolar disorder
KW - Chronic kidney disease
KW - Lithium
KW - Nephrotoxicity
KW - Renal impairment
UR - https://www.scopus.com/pages/publications/105041410157
U2 - 10.1186/s40345-026-00423-z
DO - 10.1186/s40345-026-00423-z
M3 - Article
C2 - 42034872
AN - SCOPUS:105041410157
SN - 2194-7511
VL - 14
JO - International Journal of Bipolar Disorders
JF - International Journal of Bipolar Disorders
IS - 1
M1 - 22
ER -
SDG 3 Good Health and Well-being